Salvage Robotic-assisted Laparoscopic Radical Prostatectomy Following Focal High-Intensity Focused Ultrasound for ISUP 2/3 Cancer - 30/10/21
Abstract |
Objective |
To report feasibility and outcome of salvage robotic-assisted laparoscopic radical prostatectomy (S-RALP) after focal therapy using high-intensity focused ultrasound (HIFU) treatment compared to primary robotic-assisted laparoscopic radical prostatectomy (pRALP).
Methods |
In this bicentric trial patients undergoing S-RALP for detection of WHO2016/ISUP Grade Group 2 or 3 prostate cancer were previously treated in prospective focal HIFU trials. Perioperative data, complications, oncological and functional outcome were analysed. Patients who underwent pRALP were matched in a ratio 2(pRALP):1(S-RALP) according to preoperatively functional, oncological and clinical parameters.
Results |
A total of 39 patients were included in the study (13S-RALP, 26pRALP). Median operative time in the S-RALP group was 260minutes (pRALP: 257minutes), blood loss was 230ml (pRALP: 300ml). Complications occurred in 46.2% (6/13) of S-RALP patients (pRALP: 26.9%), including four Clavien-Dindo III complications (pRALP: 2/26). In S-RALP adverse histological outcome (≥pT3a, pN+ or R1) was detected in 23.1% (3/13) (pRALP: 26.9%). There was one patient with PSA-persistence (pRALP: 2/26). Regarding functional outcomes there was no difference between the two groups observed (incontinence P=.71, erectile function P=.21).
Conclusion |
S-RALP should be offered to patients with an early relapse after focal HIFU. The early oncological outcome is satisfactory and functional outcome one year postoperatively is similar to pRALP. However, S-RALP is associated with a higher rate of Clavien-Dindo III complications (mainly, placement of a drainage), of which patients should be informed beforehand.
Le texte complet de cet article est disponible en PDF.Mots-clés : Abbreviations: AJCC, BMI, CI, EBRT, EPIC, FT, GG, HIFU, HoLEP, ICIQ, IIEF, IQR, IRB, IRE, ISUP, MRI, PCa, PDE-5-inhibitor, pRALP, PSA, RALP, RPE, S-RALP, WHO
Plan
Financial Disclosures: Ashkan Mortezavi receives funding from the Swiss Cancer League (BIL KLS-4558-08-2018). EDAP supported, in part, a Datamanager to track all HIFU patients at the University Hospital Zurich. The focal therapy trials at the University Medical Centre Mannheim are supported by the H.W. and J. Hector Foundation, Weinheim, Germany. |
Vol 156
P. 147-153 - octobre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?